[{"orgOrder":0,"company":"MEDICE Health Family","sponsor":"Erkim","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"TURKEY","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Vadadustat","moa":"Egl nine homolog 1 | Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"MEDICE Health Family","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"MEDICE Health Family \/ MEDICE Health Family","highestDevelopmentStatusID":"15","companyTruncated":"MEDICE Health Family \/ MEDICE Health Family"}]

Find Clinical Drug Pipeline Developments & Deals by MEDICE Health Family

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Under the agreement, Er-Kim partner with the MEDICE to commercialize the Vafseo (vadadustat). It is being indicated for the treatment of of symptomatic anaemia associated with CKD in adults.

                          Product Name : Vafseo

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 14, 2025

                          Lead Product(s) : Vadadustat

                          Therapeutic Area : Nephrology

                          Highest Development Status : Approved FDF

                          Recipient : Erkim

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Lead Product(s) : Restharrow Root Extract

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase III

                          Sponsor : Dr. Wiedey GmbH - Institut Für Klinische Forschung | Medidata Dr Möller

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          July 25, 2019

                          Lead Product(s) : Restharrow Root Extract

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Dr. Wiedey GmbH - Institut Für Klinische Forschung | Medidata Dr Möller

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 27, 2017

                          Lead Product(s) : Benzalkonium Chloride-Benzocaine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : University Hospital Muenster

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          October 04, 2017

                          Lead Product(s) : Sodium Bicarbonate

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Recipient : Prim. Priv. Doz. Dr. Daniel Cejka

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 14, 2010

                          Lead Product(s) : Nicotinamide

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank